Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.

MLA

Ng, Kenrick, et al. “Protocol for the EACH Trial: A Multicentre Phase II Study Evaluating the Safety and Antitumour Activity of the Combination of Avelumab, an Anti-PD-L1 Agent, and Cetuximab, as Any Line Treatment for Patients with Recurrent/Metastatic Head and Neck Squamous Cell Cancer (HNSCC) in the UK.” BMJ Open, vol. 13, no. 11, Nov. 2023, p. e070391. EBSCOhost, https://doi.org/10.1136/bmjopen-2022-070391.

APA

Ng, K., Metcalf, R., Sacco, J., Kong, A., Wheeler, G., Forsyth, S., Bhat, R., Ward, J., Ensell, L., Lowe, H., Spanswick, V., Hartley, J., White, L., Lloyd-Dehler, E., & Forster, M. (2023). Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK. BMJ Open, 13(11), e070391. https://doi.org/10.1136/bmjopen-2022-070391

Chicago

Ng, Kenrick, Rob Metcalf, Joseph Sacco, Anthony Kong, Graham Wheeler, Sharon Forsyth, Reshma Bhat, et al. 2023. “Protocol for the EACH Trial: A Multicentre Phase II Study Evaluating the Safety and Antitumour Activity of the Combination of Avelumab, an Anti-PD-L1 Agent, and Cetuximab, as Any Line Treatment for Patients with Recurrent/Metastatic Head and Neck Squamous Cell Cancer (HNSCC) in the UK.” BMJ Open 13 (11): e070391. doi:10.1136/bmjopen-2022-070391.